Nancy L. Lewis Appointed NCCN CSO
Analysis based on 8 articles · First reported Apr 09, 2026 · Last updated Apr 09, 2026
The appointment of Nancy L. Lewis as CSO of the National Comprehensive Cancer Network is expected to positively impact the healthcare and pharmaceutical markets by advancing cancer research and clinical trials. This leadership change could lead to improved oncology guidelines and innovative solutions, benefiting patients and potentially influencing the development pipelines of companies like Novartis.
The National Comprehensive Cancer Network (NCCN) has announced the appointment of Nancy L. Lewis, MD, MBS, FACP, as its new Chief Scientific Officer (CSO), effective May 2026. Dr. Lewis, an accomplished biomedical researcher with expertise in clinical trials for solid tumors and hematologic malignancies, previously served as Senior Clinical Program Leader for Novartis. In her new role, she will oversee NCCN's Oncology Research Program, Clinical Practice Guidelines in Oncology, and various compendia including Biomarkers, Radiation Therapy, and Imaging Appropriate Use Criteria. This strategic leadership enhancement aims to accelerate innovation, elevate translational research, and improve the quality, effectiveness, and accessibility of cancer care globally. Dr. Lewis succeeds Crystal S. Denlinger, who previously held the CSO position before becoming CEO.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard